On April 12, 2018 Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported it will be presenting preclinical data from its SIRPaFc immune checkpoint inhibitor programs, TTI-621 and TTI-622, at the 109th Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Trillium Therapeutics, APR 12, 2018, View Source [SID1234525284]). The meeting will be held April 14-18 in Chicago, IL. Details of the poster presentations are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: "The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis"
Presenter: Julia Bershadsky Izrailit, Ph.D., Trillium Therapeutics Inc.
Date and Time: Apr 16, 2018 from 1:00 p.m. – 5:00 p.m.
CT Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Abstract Number: 2720

Title: "TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with anti-tumor antibodies in both hematological and solid tumor models"
Presenter: Gloria Lin, Ph.D., Trillium Therapeutics Inc.
Date and Time: Apr. 16, 2018 from 1:00 p.m. – 5:00 p.m. CT
Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Abstract Number: 2709

On April 12, 2018 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release first-quarter 2018 financial results before the market opens on Thursday, April 26, 2018, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, APR 12, 2018, View Source;p=RssLanding&cat=news&id=2342215 [SID1234525285]). To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 9889627.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(PRNewsfoto/West Pharmaceutical Services, I)

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

An online archive of the broadcast will be available at the site three hours after the live call and will be available through Thursday, May 3, 2018, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International). The conference ID is 9889627.

On April 12, 2018 Active Biotech (NASDAQ STOCKHOLM: ACTI) reported that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in Chicago on April 14-18, 2018 (Press release, Active Biotech, APR 12, 2018, View Source [SID1234525482]). The poster Naptumumab Estafenatox Induces T cells Tumor Recognition, Turning anti-PD1 Unresponsive "Cold" Tumors into "Hot" Responsive Tumors will be presented between 1:00 p.m. and 5:00 p.m. local time on April 16, 2018, at the session "Immune Checkpoints 2". The data to be presented demonstrates a synergistic anti-tumor effect when ANYARA is combined with a PD-1 checkpoint inhibitor in several different tumor models that are marginally responsive to PD-1 inhibition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Checkpoint inhibitors are drugs that unleash an immune system attack against tumor cells. It is well established that a key factor that limits the effectiveness of checkpoint inhibition is tumor recognition. ANYARA is a Tumor Targeted Superantigen (TTS) that enhances the ability of the immune system to recognize and kill the tumors and is therefore attractive for combination therapy to enhance the efficacy of checkpoint inhibition.

"We are enthusiastic that our partner NeoTX has been selected to present these important data showing that ANYARA, through its tumor-targeted mode of action, enhances the effect of PD-1 inhibition and thereby potentially increases the clinical benefit of such treatment in the long term," says Helén Tuvesson, CEO of Active Biotech.

A summary of the poster presentation will be published at: View Source!/4562/presentation/9330

About ANYARA

ANYARA is a Tumor Targeting Superantigen (TTS) that enhances the ability of the immune system to recognize and kill tumors. Active Biotech has an agreement with NeoTX Therapeutics Ltd since October 2016 for the global development and commercialization of ANYARA for the treatment of cancer. Clinically, the development of ANYARA has focused on cancer forms with a high medical need. Positive data was reported from clinical Phase 1 and 2/3 studies in lung cancer, renal cell cancer and pancreatic cancer, where ANYARA was studied both as a single agent and in combination with an established tumor therapy in patients with advanced cancer. Preparations for a clinical trial in combination with a checkpoint inhibitor are ongoing.

Lund, April 12, 2018
Active Biotech AB (publ)

For further information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 20 95
Email: [email protected]

Hans Kolam, CFO
Tel. +46 46 19 20 44
Email: [email protected]

On April 12, 2018 Athersys, Inc. (Nasdaq:ATHX) reported that it will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results (Press release, Athersys, APR 12, 2018, View Source [SID1234525286]). Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date May 10, 2018
Time 4:30 p.m. (Eastern Time)
Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 1189915
Live webcast www.athersys.com under Investors section

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 24, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 1189915.

On April 11, 2018 Lytix Biopharma Reported that it will present data at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, Chicago, Illinois, US (Press release, Lytix Biopharma, APR 11, 2018, View Source
[SID1234525270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Mikael J. Pittet, Associate Professor at Harvard Medical School, Senior Faculty of the Center for Systems Biology (CSB) at Massachusetts General Hospital (MGH) and Director of the CSB Cancer Immunology Program will present the data in a poster presentation from 8-12 am on Wednesday April 18. Previous experimental studies identified LTX-315’s ability to control cancer in mice grafted with various tumor cell lines triggering tumor-specific T cells. The analyses has now been extended to conditional genetic mouse models of both melanoma (driven by Braf and Pten alterations) and soft tissue sarcoma (driven by Kras and P53 alterations). In these genetic models, cancer cells are derived from somatic cells that are transformed in their normal tissue microenvironment and progress to high-grade tumors that are poorly infiltrated by T cells and typically resist prescribed chemo- and immunotherapeutic treatments.

"We are excited to present this data at AACR (Free AACR Whitepaper) in conjunction with Dr Pittet’s team which shows that LTX-315 not only delays tumor progression substantially in both models, but also profoundly alters the tumor microenvironment, most notably characterized with CD8+ T cell, NK cell and dendritic cell infiltration. A similar transition from a ‘cold’ to a ‘hot’ tumor microenvironment is seen in patients with melanoma, sarcoma and breast cancer after treatment with LTX-315. Furthermore, CD8+ T cell depletion in mice abrogated long-term antitumor efficacy of LTX-315, indicating that these cells are required for drug-induced tumor control. Importantly, the ability to convert non-T-cell-infiltrated tumors into ones that display antitumor T cell immunity opens the possibility to prime and make unresponsive tumors sensitive for systemic immune treatments," commented Dr Edwin Klumper, CEO of Lytix Biopharma.

View Source!/4562/presentation/8122

April 18, 2018, 8:00 AM – 12:00 PM
Section 25 Session PO.CL06.08 – Immunomodulatory Agents and Interventions 3

5549 / 5 – Antitumor efficacy of the oncolytic peptide LTX-315 in genetic mouse models that resist conventional chemo- and immunotherapeutic treatments

M. J. Pittet1, H-W. Liao1, B. Sveinbjørnsson2, Ø. Rekdal2; 1Massachusetts Gen. Hosp., Boston, MA, 2Lytix Biopharma, Tromso, Norway